21,250 Shares in Bristol-Myers Squibb Co (BMY) Acquired by Ostrum Asset Management

Ostrum Asset Management bought a new stake in Bristol-Myers Squibb Co (NYSE:BMY) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 21,250 shares of the biopharmaceutical company’s stock, valued at approximately $1,344,000.

A number of other large investors have also recently modified their holdings of the stock. BlackRock Inc. increased its stake in Bristol-Myers Squibb by 5.0% in the fourth quarter. BlackRock Inc. now owns 104,293,294 shares of the biopharmaceutical company’s stock valued at $6,391,093,000 after purchasing an additional 4,945,515 shares during the last quarter. Geode Capital Management LLC increased its stake in Bristol-Myers Squibb by 4.4% in the fourth quarter. Geode Capital Management LLC now owns 18,583,469 shares of the biopharmaceutical company’s stock valued at $1,136,568,000 after purchasing an additional 777,929 shares during the last quarter. Renaissance Technologies LLC increased its stake in Bristol-Myers Squibb by 31.9% in the fourth quarter. Renaissance Technologies LLC now owns 14,302,900 shares of the biopharmaceutical company’s stock valued at $876,482,000 after purchasing an additional 3,456,300 shares during the last quarter. TIAA CREF Investment Management LLC increased its stake in Bristol-Myers Squibb by 30.8% in the fourth quarter. TIAA CREF Investment Management LLC now owns 10,932,722 shares of the biopharmaceutical company’s stock valued at $669,957,000 after purchasing an additional 2,573,967 shares during the last quarter. Finally, Orbis Allan Gray Ltd increased its stake in Bristol-Myers Squibb by 31.1% in the fourth quarter. Orbis Allan Gray Ltd now owns 6,901,670 shares of the biopharmaceutical company’s stock valued at $422,935,000 after purchasing an additional 1,635,666 shares during the last quarter. 71.37% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director Dinesh C. Paliwal purchased 4,770 shares of the firm’s stock in a transaction that occurred on Monday, April 30th. The stock was purchased at an average cost of $52.40 per share, with a total value of $249,948.00. Following the completion of the acquisition, the director now directly owns 8,027 shares in the company, valued at $420,614.80. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.12% of the stock is owned by company insiders.

Shares of Bristol-Myers Squibb opened at $53.13 on Wednesday, according to Marketbeat.com. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.52 and a quick ratio of 1.39. Bristol-Myers Squibb Co has a 1-year low of $49.96 and a 1-year high of $70.05. The firm has a market cap of $86.83 billion, a P/E ratio of 17.65, a P/E/G ratio of 1.39 and a beta of 0.95.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a return on equity of 37.56% and a net margin of 4.37%. The firm had revenue of $5.19 billion during the quarter, compared to the consensus estimate of $5.25 billion. During the same period last year, the company earned $0.84 earnings per share. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. sell-side analysts predict that Bristol-Myers Squibb Co will post 3.43 earnings per share for the current fiscal year.

Several equities analysts have commented on BMY shares. BMO Capital Markets set a $51.00 price target on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Wednesday, February 14th. Morgan Stanley upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $51.56 to $78.00 in a research report on Thursday, February 15th. Citigroup set a $78.00 target price on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Friday, February 16th. Jefferies Financial Group set a $72.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, February 26th. Finally, DZ Bank lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, February 28th. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and seven have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $62.84.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply